Clinical Trial Detail

NCT ID NCT01993719
Title Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Pembrolizumab

Aldesleukin

Fludarabine

Cyclophosphamide

Age Groups: adult

No variant requirements are available.